News
AstraZeneca Pharma gains after signing LOI with Strand Life Sciences
17-Nov-2026 | 14:29
AstraZeneca Pharma India rose 2.35% to Rs 6,183 after the company signed a Letter of Intent (LOI) with Strand Life Sciences (Strand) to explore opportunities to collaborate in healthcare in India.
Strand Life Sciences is a genomics research and diagnostics company and a subsidiary of Reliance Industries. AstraZeneca Pharma India clarified that Strand is not a related party and that the execution of the LOI does not constitute a related party transaction.
The company said the proposed engagement reflects its commitment to addressing barriers to timely diagnosis and transforming cancer care for patients across India through strategic partnerships.
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.
The company?s standalone net profit jumped 14.96% to Rs 62.33 crore in Q2 FY27 compared with Rs 54.22 crore in Q2 FY26. Net sales climbed 30.41% YoY to Rs 729.1 crore in Q2 FY27.
Powered by Capital Market - Live News